A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

This trial is testing a new drug called LYT-200 — which works by blocking a pathway that helps cancer cells hide from the immune system — in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with AML or high-risk MDS that has relapsed or is refractory (not responding) to at least one prior treatment - No standard treatment is available or you have declined available standard of care - Your ECOG performance status is 0, 1, or 2 (you are reasonably active) - Your white blood cell count is below 25,000 at the time of starting treatment - Your liver and kidney function meets the study thresholds **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific subtype of AML) - You have another active cancer besides AML or MDS - You had a bone marrow transplant from a donor within the past 6 months, or you still have active graft-versus-host disease - You have significant active central nervous system (brain) involvement from your leukemia Talk to your doctor to see if this trial is right for you.